Company News

19 March 2025

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca.

18 March 2025

Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag

The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg 100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

24 February 2025

Sandoz launches biosimilar Pyzchiva (ustekinumab-ttwe) in the US

Pyzchiva is a key biosimilar value driver for Sandoz, contributing to the company’s overall growth strategy. The company ranks number one in biosimilars globally and across key markets in Europe. The commercial availability of Pyzchiva, which builds on the US launch of Hyrimoz in July 2023, marks an important step in the Sandoz strategic ambition to become number one in biosimilars in the US.

18 February 2025

MED-EL USA gets FDA approval for cochlear implant

MED-EL USA announced that the U.S. Food and Drug Administration approved the new SONNET 3 audio processor for MED-EL cochlear implants. SONNET 3 is the companys lightest and smallest behind-the-ear audio processor and features integrated wireless direct streaming capabilities.

27 December 2024

Mankind Pharma to launch Sintilimab, advanced cancer treatment, in India

Mankind Pharma Limited and Innovent Biologics have announced a groundbreaking partnership to exclusively license and commercialise sintilimab, an advanced PD-1 immunotherapy, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region.

19 December 2024

Zydus receives final approval from USFDA for Lidocaine and Prilocaine Cream USP

Zydus Life sciences Limited has received final approval from the United States Food and Drug Administration to manufacture Lidocaine and Prilocaine Cream USP.

19 December 2024

Granules India Limited announces FDA approval for ADHD Treatment

Granules India Limited, a vertically integrated Indian pharmaceutical company, announced today that its wholly-owned foreign subsidiary, Granules Pharmaceuticals, Inc. , has received approval from the U.S. Food & Drug Administration for its Abbreviated New Drug Application for Lisdexamfetamine Dimesylate Chewable Tablets.

11 December 2024

Suven to acquire controlling stake in NJ Bio Inc.

Suven Pharmaceuticals Limited a technology-leading CDMO specializing in complex and innovative drug modalities, has announced the acquisition of a controlling stake in NJ Bio Inc. with an investment of USD 64.4 million.

31 July 2024

Zydus and Roche legal battle highlights need for affordable breast cancer treatments in India, says GlobalData

Zydus Life Sciences is engaged in a legal battle with Roche over its biosimilar, Sigrima, which is based on Roches Perjeta Pertuzumab, targeting the human epidermal growth factor receptor 2-positive breast cancer market in India.

29 July 2024

Another Indian discovered medicine, deuruxolitinib gets FDA approval against baldness

Indian Pharma giant, Sun Pharma gets the U.S. Food and Drug Administration, FDA approval for LEQSELVI deuruxolitinib 8 mg tablets for the treatment of adults with severe alopecia areata.

Search

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets

RECOMMENDED POSTS

Subscribe with us

Jobs by Category